Mei Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mei Peng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Caimei He
Hunan Normal University
1 shared publication - Jun Deng
Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research of Ministry of Education, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha 410205, China
1 shared publication - Kwame Oteng Darko
Hunan Normal University
1 shared publication - Qiongli Su
Hunan Normal University
1 shared publication - Sichun Zhou
Hunan Normal University
1 shared publication - Ting Tao
Hunan Normal University
1 shared publication
Latest Publications
- Open Access
- 27 July 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 50
Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
Background: In previous studies, we have shown that the combination of metformin and gefitinib inhibits the growth of bladder cancer cells. Here we examined whether the metformin analogue phenformin, either used alone or in combination with gefitinib, could inhibit growth of bladder cancer cells. Methods: The growth‐inhibitory effects of phenformin and gefitinib were tested in one murine and two human bladder cancer cell lines using MTT and clonogenic assays. Effects on cell migration were assessed in a wound healing assay. Synergistic action between the two drugs was assessed using CompuSyn software. The potential involvement of AMPK and EGFR pathways in the effects of phenformin and gefitinib was explored using Western blotting. Results: In MTT and clonogenic assays, phenformin was > 10‐fold more potent than metformin in inhibiting bladder cancer cell growth. Phenformin also potently inhibited cell migration in wound healing assays, and promoted apoptosis. AMPK signaling was activated; EGFR signaling was inhibited. Phenformin was synergistic with gefitinib, with the combination of drugs showing much stronger anticancer activity and apoptotic activation than phenformin alone. Conclusions: Phenformin shows potential as an effective drug against bladder cancer, either alone or in combination with gefitinib.
- 27 July 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 50
Open AccessPhenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
Background: In previous studies, we have shown that the combination of metformin and gefitinib inhibits the growth of bladder cancer cells. Here we examined whether the metformin analogue phenformin, either used alone or in combination with gefitinib, could inhibit growth of bladder cancer cells. Methods: The growth‐inhibitory effects of phenformin and gefitinib were tested in one murine and two human bladder cancer cell lines using MTT and clonogenic assays. Effects on cell migration were assessed in a wound healing assay. Synergistic action between the two drugs was assessed using CompuSyn software. The potential involvement of AMPK and EGFR pathways in the effects of phenformin and gefitinib was explored using Western blotting. Results: In MTT and clonogenic assays, phenformin was > 10‐fold more potent than metformin in inhibiting bladder cancer cell growth. Phenformin also potently inhibited cell migration in wound healing assays, and promoted apoptosis. AMPK signaling was activated; EGFR signaling was inhibited. Phenformin was synergistic with gefitinib, with the combination of drugs showing much stronger anticancer activity and apoptotic activation than phenformin alone. Conclusions: Phenformin shows potential as an effective drug against bladder cancer, either alone or in combination with gefitinib.